Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (211-220 of 269) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2024
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable TargetsMonica F Chen, Soo-Ryum Yang, Jessica J Tao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Cancer Discovery|October 18, 2023
Quantifying the Expanding Landscape of Clinical Actionability for Patients with CancerSarah P Suehnholz, Moriah H Nissan, Hongxin Zhang, et al.
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Cancer|August 31, 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancersMichael Offin, Daniel Feldman, Ai Ni, et al.
Clinical and Translational Medicine|May 29, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitorsYonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective StudySarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Pageof 27

Showing results (211-220 of 269) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2024
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable TargetsMonica F Chen, Soo-Ryum Yang, Jessica J Tao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Cancer Discovery|October 18, 2023
Quantifying the Expanding Landscape of Clinical Actionability for Patients with CancerSarah P Suehnholz, Moriah H Nissan, Hongxin Zhang, et al.
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Cancer|August 31, 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancersMichael Offin, Daniel Feldman, Ai Ni, et al.
Clinical and Translational Medicine|May 29, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitorsYonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective StudySarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Pageof 27